CorMedix Inc. Announces Signing of an Agreement with POETIC (Pediatric Oncology Experimental Therapeutics Investigators Consortium), to Develop CRMD-005, a Proprietary Formulation of Taurolidine, for Rare Orphan Pediatric Tumors
Written by cormedixadmin on September 15, 2016
Bedminster, NJ – September 15, 2016 – CorMedix Inc. (NYSE…